{"id":"forodesine","rwe":[{"pmid":"41503017","year":"2026","title":"Stereodivergent access to α- and β-azanucleosides via catalyst-free, achiral modulator-controlled iodocyclization: a concise synthesis of forodesine.","finding":"","journal":"Chemical science","studyType":"Clinical Study"},{"pmid":"41016807","year":"2025","title":"A therapeutic effect of Forodesine for CNS relapsed primary testicular T cell lymphoma after allogeneic transplantation.","finding":"","journal":"Journal of clinical and experimental hematopathology : JCEH","studyType":"Clinical Study"},{"pmid":"40848165","year":"2025","title":"Coapplication of Adenine with Inosine or Guanosine Supports Rapid ATP Restoration by ATP-deprived Cultured Primary Astrocytes.","finding":"","journal":"Neurochemical research","studyType":"Clinical Study"},{"pmid":"39230499","year":"2024","title":"Guanylate Kinase 1 Deficiency: A Novel and Potentially Treatable Mitochondrial DNA Depletion/Deletions Disease.","finding":"","journal":"Annals of neurology","studyType":"Clinical Study"},{"pmid":"38729474","year":"2024","title":"Drug repurposing for diabetes mellitus: In silico and in vitro investigation of DrugBank database for α-glucosidase inhibitors.","finding":"","journal":"International journal of biological macromolecules","studyType":"Clinical Study"}],"tags":[{"label":"Small Molecule","category":"modality"},{"label":"Purine nucleoside phosphorylase","category":"target"},{"label":"PNP","category":"gene"},{"label":"Active","category":"status"},{"label":"Peripheral T-cell lymphoma","category":"indication"},{"label":"Mundi Pharma","category":"company"}],"phase":"marketed","safety":{"safetySignals":[{"llr":83.311,"date":"","count":21,"signal":"Malignant neoplasm progression","source":"DrugCentral FAERS","actionTaken":"Reported 21 times (LLR=83)"}]},"trials":[],"aliases":[],"company":"Mundi Pharma","patents":[],"pricing":[],"_sources":{"trials":{"url":"https://clinicaltrials.gov/search?intr=FORODESINE","method":"api_direct","source":"ClinicalTrials.gov","rawText":"","confidence":1,"sourceType":"ctgov","retrievedAt":"2026-04-20T00:21:59.741900+00:00"},"regulatory.ca":{"url":"","method":"api_direct","source":"Health Canada DPD","rawText":"","confidence":1,"sourceType":"health_canada_dpd","retrievedAt":"2026-04-20T00:22:06.515470+00:00"},"publicationCount":{"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FORODESINE","method":"api_direct","source":"PubMed/NCBI","rawText":"","confidence":1,"sourceType":"pubmed","retrievedAt":"2026-04-20T00:22:07.242405+00:00"},"mechanism.target_chembl":{"url":"","method":"api_direct","source":"ChEMBL mechanism: Purine nucleoside phosphorylase inhibitor","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:22:07.814461+00:00"},"crossReferences.chemblId":{"url":"https://www.ebi.ac.uk/chembl/compound_report_card/CHEMBL550755/","method":"api_direct","source":"ChEMBL (EMBL-EBI)","rawText":"","confidence":1,"sourceType":"chembl","retrievedAt":"2026-04-20T00:22:07.720873+00:00"}},"allNames":"immucillin h","offLabel":[],"synonyms":["forodesine","forodesine hydrochloride","forodesine HCl","mundesine","fodosine","BCX-1777","Immucillin H"],"timeline":[{"date":"2017-03-30","type":"positive","source":"DrugCentral","milestone":"PMDA approval (Mundi Pharma)"}],"approvals":[{"date":"2017-03-30","orphan":false,"company":"Mundi Pharma","regulator":"PMDA"}],"brandName":"Immucillin H","ecosystem":[{"indication":"Peripheral T-cell lymphoma","otherDrugs":[{"name":"belinostat","slug":"belinostat","company":"Spectrum Pharms"},{"name":"mogamulizumab","slug":"mogamulizumab","company":"Kyowa Kirin"},{"name":"pralatrexate","slug":"pralatrexate","company":"Allos"},{"name":"romidepsin","slug":"romidepsin","company":"Celgene"}],"globalPrevalence":null}],"mechanism":{"target":"Purine nucleoside phosphorylase","targets":[{"gene":"PNP","source":"DrugCentral","target":"Purine nucleoside phosphorylase","protein":"Purine nucleoside phosphorylase"}],"modality":"Small Molecule","explanation":"","oneSentence":"","technicalDetail":"Forodesine acts as a competitive inhibitor of Purine nucleoside phosphorylase, preventing the enzyme from converting certain nucleosides into their corresponding bases, thereby increasing the intracellular concentration of these nucleosides and enhancing their cytotoxic effects on cancer cells."},"commercial":{},"references":[{"id":1,"url":"https://drugcentral.org/drugcard/5229","fields":["approvals","synonyms","ATC","PK","indications","contraindications","DDIs","targets","patents","FAERS"],"source":"DrugCentral"},{"id":2,"url":"https://clinicaltrials.gov/search?intr=FORODESINE","fields":["trials"],"source":"ClinicalTrials.gov"},{"id":3,"url":"https://pubmed.ncbi.nlm.nih.gov/?term=FORODESINE","fields":["publications"],"source":"PubMed/NCBI"}],"_enrichedAt":"2026-03-30T11:38:27.147225","_validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:22:09.560175+00:00","fieldsConflicting":1,"overallConfidence":0.8},"biosimilars":[],"competitors":[{"drugName":"sorafenib","drugSlug":"sorafenib","fdaApproval":"2005-12-20","patentExpiry":"Sep 10, 2028","patentStatus":"Patent protected","relationship":"same-target"}],"genericName":"forodesine","indications":{"approved":[{"name":"Peripheral T-cell lymphoma","source":"DrugCentral","snomedId":109977009,"regulator":"FDA"}],"offLabel":[],"pipeline":[]},"drugCategory":"active","labelChanges":[],"relatedDrugs":[{"drugId":"sorafenib","brandName":"sorafenib","genericName":"sorafenib","approvalYear":"2005","relationship":"same-target"}],"trialDetails":[{"nctId":"NCT01776411","phase":"PHASE1,PHASE2","title":"Phase I/II Clinical Study of Forodesine in Japanese Recurrent/Refractory Peripheral T-cell Lymphoma Patients","status":"COMPLETED","sponsor":"Mundipharma K.K.","startDate":"2013-01","conditions":["Recurrent or Refractory PTCL"],"enrollment":49,"completionDate":"2017-04-26"},{"nctId":"NCT00823355","phase":"PHASE1","title":"Oral Forodesine Hydrochloride (BCX-1777) in Patients With Recurrent or Refractory T/NK-cell Malignancies","status":"COMPLETED","sponsor":"Mundipharma K.K.","startDate":"2009-01","conditions":["Recurrent or Refractory T/NK-cell Malignancies"],"enrollment":24,"completionDate":""},{"nctId":"NCT00098332","phase":"PHASE1","title":"Forodesine (BCX-1777) in Treating Patients With Refractory Stage IIA, Stage IIB, Stage III, Stage IVA, or Stage IVB Cutaneous T-Cell Lymphoma","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2004-11","conditions":["Lymphoma"],"enrollment":0,"completionDate":"2011-07"},{"nctId":"NCT00061880","phase":"PHASE1,PHASE2","title":"BCX-1777 in Treating Patients With Refractory Cutaneous T-Cell Lymphoma","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2003-02","conditions":["Lymphoma"],"enrollment":0,"completionDate":"2008-01"},{"nctId":"NCT00073944","phase":"PHASE1","title":"BCX-1777 in Treating Patients With Refractory Cancer","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2003-04","conditions":["Cancer"],"enrollment":0,"completionDate":""},{"nctId":"NCT00742495","phase":"PHASE1,PHASE2","title":"Pharmacokinetic Study of Forodesine in Children With Relapsed or Refractory T-cell or B-cell Precursor Acute Lymphoblastic Leukaemia or T-cell Non- Hodgkin's Lymphoma.","status":"TERMINATED","sponsor":"Mundipharma Research Limited","startDate":"2009-03","conditions":["Relapsed or Refractory T-cell Acute Lymphoblastic Leukaemia","B-cell Precursor Acute Lymphoblastic Leukaemia","T-cell Non-Hodgkin's Lymphoma"],"enrollment":2,"completionDate":"2010-09"},{"nctId":"NCT00289549","phase":"PHASE2","title":"Study of Forodesine Hydrochloride in Patients With Advanced, Fludarabine-refractory Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2005-06","conditions":["Leukemia, Lymphocytic, Chronic"],"enrollment":8,"completionDate":"2009-01"},{"nctId":"NCT00419081","phase":"PHASE2","title":"Study of Forodesine Hydrochloride in Patients With Relapsed/Refractory Precursor T-Lymphoblastic Leukemia/Lymphoma Who Have Failed Two or More Prior Treatment Regimens","status":"TERMINATED","sponsor":"BioCryst Pharmaceuticals","startDate":"2006-07","conditions":["Leukemia","Lymphoma"],"enrollment":100,"completionDate":"2007-03"},{"nctId":"NCT00501735","phase":"PHASE2","title":"Forodesine in the Treatment of Cutaneous T-Cell Lymphoma","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2007-07","conditions":["Cutaneous T-cell Lymphoma (CTCL),"],"enrollment":144,"completionDate":"2011-12"},{"nctId":"NCT00640523","phase":"PHASE2","title":"Phase II Study of Forodesine in Subjects With Chronic Lymphocytic Leukemia (CLL)","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2008-03","conditions":["Chronic Lymphocytic Leukemia (CLL)"],"enrollment":23,"completionDate":"2011-11"},{"nctId":"NCT00289562","phase":"PHASE1,PHASE2","title":"Forodesine Hydrochloride (BCX-1777) for B-Cell Acute Lymphoblastic Leukemia","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2004-09","conditions":["B-cell Acute Lymphoblastic Leukemia"],"enrollment":20,"completionDate":"2007-12"},{"nctId":"NCT00095381","phase":"PHASE2","title":"Repeat-Dose of Forodesine Hydrochloride (BCX-1777) Infusion in Patients With Advanced T-Cell Leukemia","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2004-03","conditions":["Leukemia, T-Cell"],"enrollment":20,"completionDate":"2007-12"},{"nctId":"NCT00646165","phase":"PHASE1","title":"Trial of Forodesine in Patients With Relapsed B-cell Chronic Lymphocytic Leukemia","status":"TERMINATED","sponsor":"Mundipharma Research Limited","startDate":"2008-07","conditions":["B-cell Chronic Lymphocytic Leukemia"],"enrollment":1,"completionDate":"2009-05"},{"nctId":"NCT00035022","phase":"PHASE1,PHASE2","title":"Study of Intravenous BCX-1777 in Relapsed or Refractory Aggressive T-Cell Leukemias or Lymphomas","status":"COMPLETED","sponsor":"BioCryst Pharmaceuticals","startDate":"2001-08","conditions":["Leukemia, Lymphocytic","Lymphoma"],"enrollment":71,"completionDate":"2004-03"}],"genericFilers":[],"latestUpdates":[],"manufacturing":[],"crossReferences":{"UNII":"426X066ELK","CHEBI":"CHEBI:43362","INN_ID":"8558","UMLSCUI":"C0676720","chemblId":"CHEMBL550755","ChEMBL_ID":"CHEMBL218291","KEGG_DRUG":"D04245","DRUGBANK_ID":"DB06185","PDB_CHEM_ID":" IMH","PUBCHEM_CID":"135409409","SNOMEDCT_US":"428525005","IUPHAR_LIGAND_ID":"8272","SECONDARY_CAS_RN":"284490-13-7","MESH_SUPPLEMENTAL_RECORD_UI":"C113101"},"formularyStatus":[],"_enricherVersion":"v2","developmentCodes":[],"ownershipHistory":[{"period":"present","companyName":"Mundi Pharma","relationship":"Current Owner"}],"pharmacokinetics":{"source":"DrugCentral","halfLife":"11.6 hours","clearance":"1.56 mL/min/kg"},"publicationCount":73,"therapeuticAreas":["Oncology"],"biosimilarFilings":[],"recentPublications":[{"date":"2026 Feb 25","pmid":"41503017","title":"Stereodivergent access to α- and β-azanucleosides via catalyst-free, achiral modulator-controlled iodocyclization: a concise synthesis of forodesine.","journal":"Chemical science"},{"date":"2025","pmid":"41016807","title":"A therapeutic effect of Forodesine for CNS relapsed primary testicular T cell lymphoma after allogeneic transplantation.","journal":"Journal of clinical and experimental hematopathology : JCEH"},{"date":"2025 Aug 23","pmid":"40848165","title":"Coapplication of Adenine with Inosine or Guanosine Supports Rapid ATP Restoration by ATP-deprived Cultured Primary Astrocytes.","journal":"Neurochemical research"},{"date":"2024 Dec","pmid":"39230499","title":"Guanylate Kinase 1 Deficiency: A Novel and Potentially Treatable Mitochondrial DNA Depletion/Deletions Disease.","journal":"Annals of neurology"},{"date":"2024 Jun","pmid":"38729474","title":"Drug repurposing for diabetes mellitus: In silico and in vitro investigation of DrugBank database for α-glucosidase inhibitors.","journal":"International journal of biological macromolecules"}],"companionDiagnostics":[],"genericManufacturerList":[],"status":"approved","companyName":"Mundi Pharma","companyId":"mundi-pharma","modality":"Small molecule","firstApprovalDate":"2017","aiSummary":"","enrichmentLevel":3,"visitCount":0,"regulatoryByCountry":[{"country_code":"JP","regulator":"PMDA","status":"approved","approval_date":"2017-03-30T00:00:00.000Z","mah":"Mundi Pharma","brand_name_local":null,"application_number":""},{"country_code":"CA","regulator":"Health Canada","status":"approved","approval_date":null,"mah":"","brand_name_local":"","application_number":""},{"country_code":"US","regulator":"FDA","status":"approved","approval_date":null,"mah":null,"brand_name_local":null,"application_number":null}],"trialStats":{"total":0,"withResults":0},"validation":{"fieldsValidated":0,"lastValidatedAt":"2026-04-20T00:22:09.560175+00:00","fieldsConflicting":1,"overallConfidence":0.8},"verificationStatus":"partial","dataCompleteness":{"mechanism":false,"indications":true,"safety":false,"trials":true,"score":2}}